Entrada Therapeutics (TRDA) EBT Margin (2023 - 2025)
Historic EBT Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2693.93%.
- Entrada Therapeutics' EBT Margin fell 26127200.0% to 2693.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 169.83%, marking a year-over-year decrease of 2053500.0%. This contributed to the annual value of 31.55% for FY2024, which is 221700.0% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' EBT Margin is 2693.93%, which was down 26127200.0% from 2201.28% recorded in Q2 2025.
- Entrada Therapeutics' 5-year EBT Margin high stood at 61.03% for Q2 2024, and its period low was 2693.93% during Q3 2025.
- Moreover, its 3-year median value for EBT Margin was 12.36% (2023), whereas its average is 452.21%.
- In the last 5 years, Entrada Therapeutics' EBT Margin skyrocketed by 1275200bps in 2024 and then tumbled by -26127200bps in 2025.
- Entrada Therapeutics' EBT Margin (Quarter) stood at 22.08% in 2023, then plummeted by -109bps to 1.94% in 2024, then crashed by -139054bps to 2693.93% in 2025.
- Its EBT Margin was 2693.93% in Q3 2025, compared to 2201.28% in Q2 2025 and 84.39% in Q1 2025.